Irradiation eradication and pathogen reduction. Ceasing cesium irradiation of blood products

Mintz, Paul D.; Wehrli, Gay

doi:10.1038/bmt.2009.124

Cited by 37 publications

(20 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The work by Fast and colleagues suggests that the Mirasol system technology could be used in place of gamma irradiation for the prevention of TA‐GVHD. While the authors are appropriately cautious in their conclusions by stating that their findings “would suggest” that gamma irradiation could be replaced with PRT, this work adds to an existing strong body of experimental and clinical evidence that the Mirasol system as well as another PRT (the INTERCEPT Blood System [IBS], Cerus Corp., Concord, CA) are effective in preventing TA‐GVHD 54‐56 . For example, Fast and colleagues previously reported Mirasol system treatment of human PBMNCs before injection into mice completely prevented xenogeneic GVHD 57 …”

mentioning

confidence: 96%

See 1 more Smart Citation

Cesium cessation? An advantage of pathogen reduction treatments

Mintz¹

2011

Transfusion

View full text Add to dashboard Cite

mentioning

confidence: 96%

“…A more detailed summary of the use of the Mirasol and INTERCEPT systems to provide simultaneously strong pathogen reduction and TA‐GVHD prevention has been published 54 …”

mentioning

confidence: 99%

Cesium cessation? An advantage of pathogen reduction treatments

Mintz¹

2011

Transfusion

View full text Add to dashboard Cite

“…The PCs were leukodepleted by MachoPharma filters (Mouvaux, France) to avoid immunologically mediated effects, further possible bacterial contaminations, and infectious disease transmission (cytomegalovirus, human T-lymphotrophic virus Type I and II) 12–14. Finally, they were also treated by a gamma irradiator for 6 minutes, at the time of transfusion 16,17. The treatment and checking of the two groups were similar.…”

Section: Methodsmentioning

confidence: 99%

Application of reticulated platelets to transfusion management during autologous stem cell transplantation

Parco

Vascotto

2012

OTT

View full text Add to dashboard Cite

BackgroundThe immature (or reticulated) platelet fraction (IPF) is rich in nucleic acids, especially RNA, and can be used as a predictive factor for platelet recovery in platelet immunomediated consumption or in postchemotherapy myelosuppression. Our aim was to determine if transfusions with IPF-rich solutions, during autologous peripheral blood stem cell transplantation, reduce the occurrence of bleeding and hemorrhagic complications.Patients and methodsTransfusions were administered to 40 children, affected with hematological pathologies, who underwent autologous peripheral hematopoietic progenitor cell transplantation. There were two groups of 20 patients, one group treated with IPF-poor and the other with IPF-rich solutions. In the two groups, the conditioning regimen was the same for the same pathology (hematological pathologies: 14 acute lymphoblastic leukemia; twelve acute myelocytic leukemia; four non-Hodgkin’s lymphoma; two Hodgkin’s lymphoma; eight solid tumors). A new automated analyzer was used to quantify the IPF: the XE2100 (Sysmex, Kobe, Japan) blood cell counter with upgraded software.ResultsThe 20 patients who received solutions with a high percentage of IPF (3%–9% of total number of infused platelets) required fewer transfusions than the 20 patients who received transfusions with a low percentage of IPF (0%–1% of total number of infused platelets): 83 versus 129 (mean of number of transfusions 4.15 versus 6.45) and a significant difference was found between the two groups by using the Mann–Whitney test (P < 0.001). The prophylactic transfusions decreased from three to two per week. There was only one case of massive hemorrhage.ConclusionThe use of IPF solutions reduces the number of transfusions and bleedings after peripheral blood stem cell transplantation in pediatric patients.

show abstract

“…45 Both the Mirasol and INTERCEPT pathogen reduction systems have received CE Mark approvals and are being used in lieu of irradiation in some European countries for the prevention of TA-GVHD from apheresis platelets. 46 Other chemical compounds, such as S-303, are under investigation for pathogen reduction and prevention of TA-GVHD. 47 CONCLUSIONS TA-GVHD is a transfusion-transmitted disease and is preventable with irradiation of blood products.…”

mentioning

confidence: 99%

Prevention of Transfusion-Associated Graft-Versus-Host Disease With Blood Product Irradiation: The Past, Present, and Future

Bahar¹,

Tormey

2018

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Transfusion-associated graft-versus-host disease (TA-GVHD) is a disease with a very high mortality rate. In this report, we discuss TA-GVHD from a historical perspective, highlight the pathogenesis of TA-GVHD, and emphasize the importance of blood product irradiation, which is a very effective means to prevent this disease. We summarize the current recommendations in different patient populations from different countries and review recent developments, such as alternatives for the use of radioactive materials. We also speculate on future directions.

show abstract

Irradiation eradication and pathogen reduction. Ceasing cesium irradiation of blood products

Cited by 37 publications

References 30 publications

Cesium cessation? An advantage of pathogen reduction treatments

Cesium cessation? An advantage of pathogen reduction treatments

Application of reticulated platelets to transfusion management during autologous stem cell transplantation

Prevention of Transfusion-Associated Graft-Versus-Host Disease With Blood Product Irradiation: The Past, Present, and Future

Contact Info

Product

Resources

About